These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16211062)

  • 1. Antibodies in the breakdown lane.
    Blumberg RS; Lencer WI
    Nat Biotechnol; 2005 Oct; 23(10):1232-4. PubMed ID: 16211062
    [No Abstract]   [Full Text] [Related]  

  • 2. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
    Vaccaro C; Zhou J; Ober RJ; Ward ES
    Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kill 'Em All: Efgartigimod Immunotherapy for Autoimmune Diseases.
    Bayry J; Kaveri SV
    Trends Pharmacol Sci; 2018 Nov; 39(11):919-922. PubMed ID: 30201270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
    Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
    J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered clearing agents for the selective depletion of antigen-specific antibodies.
    Devanaboyina SC; Khare P; Challa DK; Ober RJ; Ward ES
    Nat Commun; 2017 May; 8():15314. PubMed ID: 28561044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and function of human and murine receptors for IgG.
    Unkeless JC; Scigliano E; Freedman VH
    Annu Rev Immunol; 1988; 6():251-81. PubMed ID: 2968084
    [No Abstract]   [Full Text] [Related]  

  • 8. Fc-dependent mechanisms of action: roles of FcγR and FcRn.
    Kuijpers T
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):89-91. PubMed ID: 25546775
    [No Abstract]   [Full Text] [Related]  

  • 9. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.
    Sockolosky JT; Szoka FC
    Adv Drug Deliv Rev; 2015 Aug; 91():109-24. PubMed ID: 25703189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering therapeutic monoclonal antibodies.
    Liu XY; Pop LM; Vitetta ES
    Immunol Rev; 2008 Apr; 222():9-27. PubMed ID: 18363992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: Antibody Fc Engineering: Towards Better Therapeutics.
    Lei C; Gong R; Ying T
    Front Immunol; 2018; 9():2450. PubMed ID: 30405636
    [No Abstract]   [Full Text] [Related]  

  • 12. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
    Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
    MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences.
    Sibéril S; Dutertre CA; Boix C; Bonnin E; Ménez R; Stura E; Jorieux S; Fridman WH; Teillaud JL
    Immunol Lett; 2006 Aug; 106(2):111-8. PubMed ID: 16797726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
    Pollastrini J; Dillon TM; Bondarenko P; Chou RY
    Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.
    Vaccaro C; Bawdon R; Wanjie S; Ober RJ; Ward ES
    Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18709-14. PubMed ID: 17116867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics (PK) of mAbs].
    Paintaud G
    Med Sci (Paris); 2009 Dec; 25(12):1057-62. PubMed ID: 20035679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isotype selection in antibody engineering.
    Salfeld JG
    Nat Biotechnol; 2007 Dec; 25(12):1369-72. PubMed ID: 18066027
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor.
    Oksenhendler E
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):92-3. PubMed ID: 25546776
    [No Abstract]   [Full Text] [Related]  

  • 19. Tailoring natural effector functions. Antibody engineering beyond humanization.
    Brekke OH; Thommesen JE
    Methods Mol Biol; 2003; 207():383-91. PubMed ID: 12412487
    [No Abstract]   [Full Text] [Related]  

  • 20. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.